| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $26.0M | +6.7% |
| Cost of Revenue | $3.0M | +7.7% |
| R&D Expense | $51.0M | +4.3% |
| SG&A Expense | $36.7M | -17.5% |
| Operating Income | -$67.5M | +6.2% |
| Pre-tax Income | -$63.7M | +3.2% |
| Income Tax | $0 | — |
| Net Income | -$63.7M | +3.2% |
| EPS (Basic) | -$2.36 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $28.7M | -54.4% |
| Short-term Investments | $18.6M | -59.6% |
| Accounts Receivable | $5.9M | +7.6% |
| Inventory | $5.3M | -17.4% |
| Current Assets | $61.3M | -50.8% |
| Total Assets | $70.3M | -46.9% |
| Current Liabilities | $17.1M | -35.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$59.5M | +0.2% |
| Capital Expenditures | $1.7M | -58.4% |
| Investing Cash Flow | $25.2M | -69.7% |
| Financing Cash Flow | $130K | -60.1% |
| Free Cash Flow | -$61.2M | +3.8% |
| +3.3% |
| EPS (Diluted) | -$2.36 | +3.3% |
| Total Liabilities |
| $17.8M |
| -34.5% |
| Stockholders' Equity | $52.5M | -50.1% |